Uppsala, Sweden - May 29, 2015 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,399,723 shares and votes in the company. For further information, please contact: Henrik Juuel, EVP and Chief Financial Officer Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About Orexo Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden. For information about Orexo please visit www.orexo.com Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 5:30 pm CET on May 29, 2015.
Number of shares and votes in Orexo
| Source: Orexo AB
Attachments
